Eric Venker
President chez ROIVANT SCIENCES LTD.
Fortune : 5 M $ au 31/03/2024
Profil
Actuellement, Eric Venker est coprésident et directeur d'exploitation de Roivant Sciences Ltd, président et directeur d'exploitation de Roivant Sciences, Inc. et coprésident et directeur d'exploitation de Roivant Sciences GmbH (toutes deux filiales de Roivant Sciences Ltd) et coprésident et directeur d'exploitation de Montes Archimedes Acquisition Corp. Eric Venker siège également au conseil d'administration d'Arbutus Biopharma Corp, de Sio Gene Therapies, Inc, d'Aruvant Sciences, Inc et d'Immunovant, Inc. Il a précédemment occupé le poste de président du conseil de la qualité du personnel au Columbia University Medical Center. Eric Venker est titulaire d'un doctorat de la Yale School of Medicine et d'un doctorat du St. Louis College of Pharmacy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ROIVANT SCIENCES LTD.
0,06% | 20/03/2024 | 500 202 ( 0,06% ) | 5 M $ | 31/03/2024 |
Postes actifs de Eric Venker
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 18/02/2020 |
| ROIVANT SCIENCES LTD. | President | 01/01/2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | President | 01/01/2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Director/Board Member | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Chief Operating Officer | - |
| Roivant Social Ventures, Inc. | Director/Board Member | 01/01/2014 |
Anciens postes connus de Eric Venker
| Sociétés | Poste | Fin |
|---|---|---|
| SIO GENE THERAPIES INC. | Director/Board Member | 05/04/2023 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 25/05/2022 |
| ROIVANT SCIENCES LTD. | President | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Eric Venker
| St. Louis College of Pharmacy | Doctorate Degree |
| Yale School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| ROIVANT SCIENCES LTD. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
| Roivant Social Ventures, Inc. |
